The overall goal of the University of Iowa MDCRC is to explore therapeutic strategies for the treatment of various muscular dystrophies arising from the abnormal processing of dystroglycan (dystroglycanopathies). The Center will achieve this overall goal by enabling translational research on the dystroglycanopathies and providing advanced diagnostic services. Our MDCRC application is composed of two projects, three cores, and investigators with a proven track record of excellence and collaboration in basic, translational and clinical research. Project 1 will investigate the molecular pathogenesis of the dystroglycanopathies and evaluate various therapeutic strategies, using defined mouse models and dystroglycanopathy patient cells with known mutations. Kevin Campbell will lead this translational project and Steven Moore and Francesco Muntoni will participate in it. A major asset for this project is our recently awarded """"""""GO grant"""""""" aimed at the discovery of small molecule effectors of dystroglycan glycosylation. Project 2 will identify and characterize dystroglycanopathy patients and develop infrastructure for therapeutic trials in defined cohorts. Katherine Mathews will be the project leader on this clinical project with participation from Carsten Bonnemann. Core A (Campbell and Moore) is an administrative core and will coordinate the activities within and outside the Center as a means to promote an interactive and collaborative research environment. Core B (Moore), a Muscle-Tissue/Cell-Culture/Diagnostics Core, will serve as a national tissue and cell-culture resource for research, as well as a laboratory for patient diagnostic testing and post-intervention biopsy evaluation for clinical trials. Finally, Core C (Campbell and Mathews) will coordinate our Research Training and Education initiative. Among the support it provides will be a fellowship enabling one medical student per year to perform research in the Center and to participate in the care of patients alongside Katherine Mathews. Thus, the highly integrated cores and projects, coupled with the expanded collaboration with national and international leaders in the field of dystroglycanopathies, will accelerate the tempo of discovery in preclinical translational research, and establish the clinical-trial readiness of a cohort of dystroglycanopathy patients.

Public Health Relevance

Our MDCRC renewal promotes the NIH mission by enabling pre-clinical and clinical translational research on the dystroglycanopathies, providing advanced diagnostic services and training of basic and clinical scientists. The coordinated focus of the five integrated cores and projects is to translate basic science research discoveries into the diagnosis and treatment of patients with dystroglycan-associated muscular dystrophies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS053672-09
Application #
8477312
Study Section
Special Emphasis Panel (ZNS1-SRB-S (22))
Program Officer
Porter, John D
Project Start
2005-04-01
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$1,438,714
Indirect Cost
$484,801
Name
University of Iowa
Department
Physiology
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Lee, Angela J; Buckingham, Edward T; Kauer, Aaron J et al. (2018) Descriptive Phenotype of Obsessive Compulsive Symptoms in Males With Duchenne Muscular Dystrophy. J Child Neurol 33:572-579
González Coraspe, José Andrés; Weis, Joachim; Anderson, Mary E et al. (2018) Biochemical and pathological changes result from mutated Caveolin-3 in muscle. Skelet Muscle 8:28
Martinez-Thompson, Jennifer M; Niu, Zhiyv; Tracy, Jennifer A et al. (2018) Autosomal dominant calpainopathy due to heterozygous CAPN3 C.643_663del21. Muscle Nerve 57:679-683
Brun, Brianna N; Willer, Tobias; Darbro, Benjamin W et al. (2018) Uniparental disomy unveils a novel recessive mutation in POMT2. Neuromuscul Disord 28:592-596
Larson, Austin A; Baker 2nd, Peter R; Milev, Miroslav P et al. (2018) TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of ?-dystroglycan and muscular dystrophy. Skelet Muscle 8:17
Carlson, Courtney R; Moore, Steven A; Mathews, Katherine D (2018) Dystrophinopathy muscle biopsies in the genetic testing ERA: One center's data. Muscle Nerve :
Brun, Brianna N; Mockler, Shelley R H; Laubscher, Katie M et al. (2017) Comparison of brain MRI findings with language and motor function in the dystroglycanopathies. Neurology 88:623-629
Carlson, Courtney R; McGaughey, Steven D; Eskuri, Jamie M et al. (2017) Illness-associated muscle weakness in dystroglycanopathies. Neurology 89:2374-2380
Donkervoort, Sandra; Chan, Sophelia H S; Hayes, Leslie H et al. (2017) Cytoplasmic body pathology in severe ACTA1-related myopathy in the absence of typical nemaline rods. Neuromuscul Disord 27:531-536
Wilson, Kristin; Faelan, Crystal; Patterson-Kane, Janet C et al. (2017) Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification. Toxicol Pathol 45:961-976

Showing the most recent 10 out of 97 publications